LIVE TV
ZEE Business
ZEE BUSINESS
हिंदी में पढ़ें  हिंदी में पढ़ें
Live TV
Live TV
  • Home
  • Budget 2021
  • Personal Finance
    • PPF
    • Mutual Funds
    • Income tax
    • EPFO
    • Income Tax Calculator
    • Personal Loan Calculator
    • Car Loan Calculator
    • Home Loan Calculator
    • SIP calculator
    • SWP Calculator
    • MF Returns Calculator
    • Lumpsum Calculator
  • India
    • Companies
    • Property
    • Startups
    • Uidai
  • Economy
    • Aviation
  • Tech
    • Mobiles
    • Apps
  • Auto
    • Cars
    • Bikes
  • Markets
    • Commodities
    • Currency
  • Jobs
  • Indian Railways
  • World
    • Economy
    • Politics
    • Markets
  • videos
  • photos
  • Authors
  • More ...
    • VIDEOS
    • PHOTOS

Read in App
Business News » World News

Mylan surges, Teva slumps after FDA approves Copaxone copy

  • Twitter
  • Facebook
  • Linkedin
  • whatapp
  • View in App
Updated: Thu, Oct 05, 2017
09:52 am
Reuters
RELATED NEWS
Expert Views: BIG! India's retail inflation eases to 4.59% in December Expert Views: BIG! India's retail inflation eases to 4.59% in December
Budget 2021 Expectations – HOME BUYERS to benefit if Govt accepts this demand; JLL CEO lists following demands Budget 2021 Expectations – HOME BUYERS to benefit if Govt accepts this demand; JLL CEO lists following demands
Jobs, land prices, Covid-19 vaccine, rural India, household savings, NBFCs, banks, consumption, capex - Positives and Negatives | EXPLAINED Jobs, land prices, Covid-19 vaccine, rural India, household savings, NBFCs, banks, consumption, capex - Positives and Negatives | EXPLAINED
Economy, markets, FIIs, chemicals, IT and Pharma - Make money, as India powers to new highs | EXPLAINED    Economy, markets, FIIs, chemicals, IT and Pharma - Make money, as India powers to new highs | EXPLAINED
Setback for China – Trend reversing in favour of India; SFI lands big blow! Know here WHY! Setback for China – Trend reversing in favour of India; SFI lands big blow! Know here WHY!

Mylan NV`s long-awaited U.S. approval for its generic version of rival Teva`s blockbuster multiple sclerosis treatment Copaxone drove Mylan`s shares up around 18 percent on Wednesday while Teva shares plunged.

The approval late on Tuesday by the U.S. Food and Drug Administration came earlier than both companies had expected. It was issued a day after the health regulator said it would introduce measures to speed to market generic versions of complex drugs like Copaxone to help address the rising cost of pharmaceuticals.

Copaxone is the leading MS therapy worldwide as well as Teva`s best-selling drug, generating more than $4 billion in revenue for the Israeli drugmaker last year.

On Wednesday, Teva`s U.S.-listed shares sank 14 percent to $16.17, while Mylan`s shares rose $5.96 to $38.48.

Teva said that Mylan was launching the drug before resolving various patent appeals, meaning that Mylan may risk having to pay damages if Teva prevails.

The FDA approved two different doses of Mylan`s version of the drug, 20 mg and 40 mg. The 40 mg dosage accounted for more than 85 percent of Copaxone prescriptions in the second quarter.

Analysts called the approval a big win for Mylan and said it would help 2017 and 2018 earnings. Mylan filed its first application for a version of Copaxone in 2009.

Wells Fargo analyst David Maris said that optimistically the drug could add 13 cents a share to Mylan`s quarterly earnings going forward. That assumes Mylan captures a 40 percent share of the 40 mg dosage market at a 40 percent discount to Teva`s pricing.

Mylan had lowered its 2017 and 2018 earnings forecast in August, due in part to delays getting FDA approvals for key generics like its versions of Copaxone and asthma treatment Advair. At the time it said it did not expect any major product launches until 2018.

After the approval Mylan said it expected to start shipping its generic drug very soon. The FDA approval letter also said the company might be eligible for 180 days exclusivity on the drug, Mylan reported.

Momenta Pharmaceuticals and the Sandoz unit of Novartis already sell a generic version of 20 mg Copaxone and are developing a version of the 40 mg dosage.

But their difficulties in getting the higher-dose version approved had dampened expectations for Mylan before Tuesday. Momenta said the companies would still be able to launch during any exclusivity period if they receive approval.

JPMorgan analysts said Teva now faces full generic competition for Copaxone nine to 12 months earlier than expected. Teva has already been hurting due to weak generics prices in the United States and high debt.

Last month, Teva said it was looking to team up with other drugmakers to fund some of its development pipeline as it struggles with debt and expiring patents. The drugmaker`s specialty business has been losing ground since Copaxone ran out of patents.

In August, a U.S. House of Representatives committee contacted Teva, Novartis and five other makers of multiple sclerosis drugs as part of a drug pricing investigation, saying that some of the dozen drugs used to treat the progressive neurological disease appeared to have lockstep price increases.

The 2017 price for the 40 mg version of Copaxone is $80,000 per year and the 20 mg version is more than $90,000 after having been launched in 1996 at just over $8,000, the House committee said.

Shares of Biogen Inc, another maker of MS drugs, fell 1.4 percent to $315.99. Momenta shares fell 15 percent, or $2.65, to $14.85.

(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.

TAGS:
Economy
RELATED NEWS
Expert Views: BIG! India's retail inflation eases to 4.59% in December Expert Views: BIG! India's retail inflation eases to 4.59% in December
Budget 2021 Expectations – HOME BUYERS to benefit if Govt accepts this demand; JLL CEO lists following demands Budget 2021 Expectations – HOME BUYERS to benefit if Govt accepts this demand; JLL CEO lists following demands
Jobs, land prices, Covid-19 vaccine, rural India, household savings, NBFCs, banks, consumption, capex - Positives and Negatives | EXPLAINED Jobs, land prices, Covid-19 vaccine, rural India, household savings, NBFCs, banks, consumption, capex - Positives and Negatives | EXPLAINED
Economy, markets, FIIs, chemicals, IT and Pharma - Make money, as India powers to new highs | EXPLAINED    Economy, markets, FIIs, chemicals, IT and Pharma - Make money, as India powers to new highs | EXPLAINED
Setback for China – Trend reversing in favour of India; SFI lands big blow! Know here WHY! Setback for China – Trend reversing in favour of India; SFI lands big blow! Know here WHY!

LATEST NEWS

FAUG Game Download: Big development! Here is link

CBSE Class 10, Class 12 exams 2021: Datasheet announcement in March? What past trends suggest and possible reasons for delay

Stock Market Tips With Anil Singhvi: Vikas Sethi recommends these two fabulous shares to buy for whopping returns

Amazing pagdi! PM Narendra Modi's turban pics go viral! Know story behind headgear and who gifted it

Crackdown on income tax evaders! Critical notification by CBDT on evasion, Benami Property, Black Money - PAN, Aadhaar not needed, just do this online now

Big BSNL prepaid plans offer on Republic Day 2021; just check out the benefits

Kannada actress Jayashree Ramaiah found dead

Two biz lessons from India vs Australia Cricket Test Match, straight from the Fund Manager's desk

SBI MF Retirement Benefit Scheme: 200% returns than FD! Term insurance of up to Rs 50 lakh! Should you invest? EXPLAINED

SECI Recruitment 2021: Salary up to Rs 2 lakh! Apply on seci.co.in; check eligibility, last date and other details

  • India News
  • World News
  • Companies News
  • Market News
  • Personal Finance News
  • Technology News
  • Automobile News
  • Small Business News
  • Income Tax Calculator
  • Live TV
  • Videos
  • Photos
  • Author
  • Rss Feed
  • Advertise with us
  • Privacy Policy
  • Legal Disclaimer

Latest Trending Updates

  • EPFO
  • Budget 2020
  • Income Tax Return
  • Auto Expo 2020
  • Home Loan
  • Business News

Trending Topics

  • Income Tax
  • income Tax Calculator
  • 7th Pay Commission
  • Reserve Bank of India
  • GST
  • Latest Business News

Follow us on

zeebiz
zeebiz

Partner Sites

  • Zee News
  • Hindi News
  • Marathi News
  • Bengali News
  • Tamil News
  • Malayalam News
  • Gujarati News
  • Telugu News
  • Kannada News
  • DNA
  • WION
Copyright © Zee Media Corporation Ltd. All rights reserved